Journal
BLOOD CANCER JOURNAL
Volume 12, Issue 11, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41408-022-00756-9
Keywords
-
Categories
Ask authors/readers for more resources
The introduction of oral targeted therapies and next-generation anti-CD20 monoclonal antibodies has significantly changed the treatment landscape for patients with chronic lymphocytic leukemia (CLL). These treatments lead to improved outcomes, even in high-risk patients. Selecting the right treatment requires consideration of disease characteristics, treatment sequence, patient preferences, and comorbidities.
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very effective oral targeted therapies (such as Bruton tyrosine kinase inhibitors and venetoclax) and next-generation anti-CD20 monoclonal antibodies (such as obinutuzumab). These agents lead to improved outcomes in patients with CLL, even among those with high-risk features, such as del17p13 or TP53 mutation and unmutated immunoglobulin heavy chain (IGHV) genes. Selecting the right treatment for the right patient requires consideration of disease characteristics and prior treatment sequence, as well as patient preferences and comorbidities. The CLL-International Prognostic Index (CLL-IPI) remains the best-validated tool in predicting the time to first therapy among previously untreated patients, which guides selection for early intervention efforts. This review summarizes our current approach to the management of CLL, right from the time of diagnosis through relapsed disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available